Aspen Dangles £700M Bid For GSK Drugs
The deal includes £100 million to purchase existing inventory, according to GSK's second-quarter earnings report. Aspen and GSK have been negotiating under an exclusivity period since last month, when they first announced the possible sale without disclosing the potential value of the deal.
Representatives for GSK declined to comment further Wednesday. Representatives for Aspen...
To view the full article, register now.